Garnick was the regulatory architect for PPHM in the 2nd line trial and is probably as well-versed in clinical trial design as most BV posters. Do you find it curious that Garnick wouldn't put such a "basic" safeguard in place?
I don't know. Masterlongevity in a subsequent post said something to the effect, when asked about Garnick, that Garnick wasn't involved in the nitty-gritty of running trials at Genentech.
It would take me too long to go back and find the post. I'm just back from a long vacation, I'm not well and, on top of that, I'm doing a mountain of sandy laundry...
I think asking him yourself about it would be the easiest way to get his view as to whether or not Garnick would have known to put such a safeguard in place and why, if he did, such safeguards were not put in place.
From my own point of view, as an investor, that's water under the bridge. The question now is, what's going to happen with the PIIb 1st Line data. That, to me, is the clearest near-term inflection point. Specifically, the question becomes, does one wait to find out the new data before investing or jump in later on good data?
I'm now leaning towards the latter. Call me cautious.
Market Data 
Markets 
AI
